Main navigation

• Home
• About us
• Medicines
• Research
• Careers
• Responsibility
• Partnering
• Media
• Investors
  • Directors' shareholdings
  • Financial calendar
  • Annual reports
  • Financial highlights
  • Strategy
  • Investor contacts
  • Corporate governance
  • Shareholder information
  • Investor tools
  • SEC filings
  • Financial results
  • Presentations & webcasts
  • FAQs

You are here

• Home

• Investor relations

• Latest news collapse

  • 18 November 2009 Results from Two Phase II Trials Add to Understanding of Brilinta (Ticagrelor) and How it Works in the Body

    AstraZeneca today announced the results of the phase II studies, ONSET/OFFSET and RESPOND for ticagrelor (BRILINTA) at the annual American Heart Association (AHA) Scientific Sessions in Orlando, FL, with ONSET/OFFSET study results being simultaneously published in the medical journal Circulation.

  more news

  • previous
  • • 1
    • 2
    • 3
    • 4
    • 5
  • next

  Research & Development collapse

  We focus our research on six disease areas where we believe our skills and experience can make the most difference.

  • Read about our disease area focus
  • Read about our pipeline progress
  • Review our pipeline summary

  Share price tools collapse

  • Interactive stock charts
  • Share holding calculator
  • Share price look-up
  • Share price history

• Annual Report 2008 collapse

  • Online annual report
  • Order a printed copy

  Latest presentation collapse

  November 2009

  • Investor Relations general presentation (PDF 3 Mb)

  • Other presentations

  Financial results collapse

  Third Quarter & Nine Months results 2009 announced Thursday, 29 October 2009.

  • View details of the event
  • View financial calendar

  Managing your shares collapse

  • Dividend information
  • Shareholder forms
  • Share registration contacts
  • Annual General Meeting
  • FAQs

  Currency Guidance 2009 collapse

  • View 2009 currency guidance

Not signed in

Page tools

• Print
• Bookmark this page

Share price